research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
Search
for
Sort by
Research
30 / 1000+ results 
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
Disease-specific tools better assess quality of life in alopecia areata patients.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research [ADAPTIVE REGULATORY MECHANISMS OF ALOPECIA AREATA].
Alopecia areata progression is linked to stress and hormone changes, suggesting new treatment targets.
research The Changing Landscape of Alopecia Areata: The Translational Landscape
New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.
research A study of clinical and dermoscopic features in alopecia areata at a tertiary referral center
The study concluded that short vellus hair and yellow dots were the most common signs of alopecia areata, indicating disease activity and remission.
research Assessment of prognostic markers of alopecia areata in pediatric patients
Early diagnosis and treatment of alopecia areata in children is crucial to prevent severe progression.
research Dermoscopic evaluation of therapeutic response to intralesional triamcinolone acetonide in the treatment of Alopecia areata
Intralesional triamcinolone acetonide effectively treats alopecia areata, as shown by significant improvements in hair regrowth and dermoscopic indicators.
research Topical Mechlorethamine Restores Autoimmune-Arrested Follicular Activity in Mice with an Alopecia Areata-Like Disease by Targeting Infiltrated Lymphocytes
Mechlorethamine treatment regrew hair in mice by killing immune cells causing hair loss without harming hair follicles.
research Serum Granulysin Levels in Vitiligo and Alopecia Areata: A Potential Biomarker for Disease Activity and Dermoscopic Evaluation
Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.
research Alopecia areata: trichoscopic markers in determining disease activity
Exclamation mark hairs and broken hairs best indicate active alopecia areata.
research DIAGNOSTIC VALUE OF TRICHOSCOPY IN THE DIFFERENTIAL DIAGNOSIS OF VARIOUS FORMS OF ALOPECIA
Trichoscopy is essential for accurately diagnosing and differentiating types of hair loss.
research Gene Expression of CD70 and CD27 Is Increased in Alopecia Areata Lesions and Associated with Disease Severity and Activity
Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
Baseline severity and relapse history affect alopecia areata treatment and recurrence.
research Clinical and Trichoscopic Patterns of Hair Loss in Systemic Lupus Erythematosus and its Correlation with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.
research Serum IL-21 Level and Its Relation to Activity and Severity of Alopecia Areata
Higher IL-21 levels may help predict alopecia areata activity.
research Oxidative Stress in Alopecia Areata and its Association with Disease Severity, Treatment and Autoimmunity
Corticosteroids may not effectively control oxidative stress in alopecia areata, possibly leading to relapses.
research Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
research Thyroid hormone action on skin.
Thyroid hormones affect skin texture, hair and nail growth, and can cause skin diseases related to thyroid problems.
research New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals
Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.
research Trichoscopic signs in systemic lupus erythematosus: a comparative study with 109 patients and 305 healthy controls
Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.
research The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances
BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
research Serum 25-Hydroxy Vitamin D Level in Patients with Alopecia Areata and Its Relationship with Severity of the Disease
Lower vitamin D levels are linked to more severe alopecia areata.
research Th1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
research 218 Chemokine receptor CCR5 is the novel target for the treatment of alopecia areata
Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
research Assessment of Alopecia Areata Disease Severity in Pediatric Patients
New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.